Abstract: A method compensates for leakage currents in a protective conductor of an electrical power converter.

Abstract: The present invention relates to the recognition of CSF1R as a marker of hematological cancer and thus relates to CSF1R targeting agents for the treatment of such cancers, in particular, AML. The invention also relates to a lymphocyte recombinantly expressing a chimeric antigen T cell receptor (CAR) specific for CSF1R, in particular, for use in the treatment of cancer characterized by the expression of colony stimulating factor 1 receptor (CSF1R). The present invention further relates to a CAR comprising an extracellular domain that specifically binds CSF1R, a transmembrane domain, and an intracellular T cell activating domain; as well as polynucleotides, vectors and host cells used in the production of the CAR. Further, methods for the production of such lymphocytes and a pharmaceutical composition comprising such lymphocytes are provided.

Abstract: A method compensates for leakage currents in a protective conductor of an electrical power converter.

Abstract: A rectifier arrangement for rectifying an AC voltage into a DC voltage has connections, circuit arrangements, an interconnection apparatus and an intermediate circuit. Each circuit arrangement has first and second circuit arrangement connections, between which a changeover arrangement and a coil are connected in series with the changeover arrangement. The changeover arrangements are interconnected to the intermediate circuit. The interconnection apparatus is designed to enable at least a first configuration and a second configuration. In the first configuration, the circuit arrangements form a first group and a second group, with two connections connected to the circuit arrangements in the first group, but not to the circuit arrangements in the second group, and two connections are connected to the circuit arrangements in the second group, but not to the circuit arrangements in the first group. In the second configuration, at least one of the connections is connected to all circuit arrangements.

Abstract: Provided is a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor. The (bispecific) antibody molecules can be used in a method for the treatment of particular diseases, wherein the (bispecific) antibody molecules are administered in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor in a specific treatment regimen.

Abstract: The present invention relates to CXCR6-transduced (a) T cell(s) such as (a) CD8+ T cell(s), (a) CD4+ T cell(s), (a) CD3+ T cell(s), (a) ?? T cell(s) or (a) natural killer (NK) T cell(s) for targeted tumor therapy, nucleic acid sequences, vectors capable of transducing such (a) T cell(s), (a) transduced T cell(s) carrying the nucleic acid sequences or vectors of the present invention, methods and kits comprising the nucleic acid sequences or vectors of the present invention. The invention also provides the use of said transduced T cell(s) in a method for the treatment of diseases characterized by CXCL16 overexpression as well as a pharmaceutical composition/medicament comprising (a) transduced T cell(s) expressing the CXCR6 for use in methods of treating diseases characterized by CXCL16 overexpression.

Abstract: A DC filter device includes: a first filter device connection; a second filter device connection; a third filter device connection; a fourth filter device connection; a coil core; at least one first coil arranged on the coil core, the at least one first coil being connected in between the first filter device connection and the third filter device connection; at least one second coil arranged on the coil core, the at least one second coil being connected in between the second filter device connection and the fourth filter device connection; and a third coil arranged on the coil core, the third coil having a first coil connection and a second coil connection. The first coil connection and the second coil connection are connected to one another via a circuit device, which circuit device has a resistor.

Abstract: A rectifier arrangement (20) for rectifying an AC voltage into a DC voltage has connections, circuit arrangements, an interconnection apparatus (26) and an intermediate circuit (50). The connections include first and second connections (22, 21). The intermediate circuit (50) has a first line (51), a second line (52) and at least one capacitor (61, 62) between the first and second lines (51, 52). The circuit arrangements (31, 32, 33, 34, 35, 36) each have a first circuit arrangement connection (A) and a second circuit arrangement connection (B), between which a changeover arrangement (92) and a coil (91) are connected in series. The interconnection apparatus (26) enables at least: a first configuration in which the first connection (22) is connected to at least one first circuit arrangement connection (A), and a second configuration in which the first connection (22) is connected to at least one second circuit arrangement connection (B).

Abstract: The present invention generally relates to T-cells, such as CD8+ T-cells, CD4+ T-cells, CD3+ T-cells, ?? T-cells or natural killer (NK) T-cells, transfected/transduced with a fusion protein which is recruited by the use of trivalent, bispecific antibody molecule which specifically binds to/interacts with the extracellular domain of the fusion protein. More precisely, the present invention relates to a kit comprising the nucleic acid molecules, vectors and/or the fusion proteins of the present invention and the trivalent, bispecific antibody molecules of the present invention. Further aspects of the inventions are expression vectors comprising nucleic acid molecules encoding the fusion proteins as well as the trivalent, bispecific antibody molecules. Further, a process for the production of the trivalent, bispecific antibody molecules of the invention and a medicament/pharmaceutical composition comprising said trivalent, bispecific antibody molecules are described.

Abstract: A compensation device (20) for compensating for a discharge current has a compensation current generation device (28), a potential generation device (150), active conductor terminals (61, 62, 63, 64) and a PE conductor terminal (65), which active conductor terminals (61, 62, 63, 64) have a first active conductor terminal (61) and a second active conductor terminal (62; 64), which potential generation device (150) is interconnected with the first active conductor terminal (61) and has a potential generation device terminal (155), which potential generation device (150) is designed to provide a potential at the potential generation device terminal (155) which at least temporarily differs from the potential at the first active conductor terminal (61), and which compensation current generation device (28) is designed to effect a compensation current (I_COMP) between the potential generation device terminal (155) and the PE conductor terminal (65).

Abstract: The present invention relates to PD-1-CD28 fusion proteins, nucleic acid molecules, vectors, transduced cells carrying nucleic acid molecules or vectors of the present invention or expressing the fusion proteins of the present invention, methods and kits comprising the nucleic acid molecules, vectors and/or the fusion proteins of the present invention. The invention also provides the use of said transduced cells in a method for the treatment of particular diseases as well as a pharmaceutical composition/medicament comprising said transduced cells expressing the fusion proteins of the present invention for use in a method of treating of diseases, in particular in the medical intervention of diseases characterized by PD-L1 and/or PD-L2 expression.

Abstract: The present invention relates to lymphocytes genetically engineered to express a CCR8 polypeptide or a functional variant thereof for use in targeted tumor immunotherapies such as adoptive T cell therapy.

Abstract: A rectifier arrangement (20) for rectifying an AC voltage into a DC voltage has a first connection (21), a second connection (22), a third connection (23) and a fourth connection (24), which rectifier arrangement (20) has an intermediate circuit (50) with a first line (51), a second line (52) and a node point (53), which node point (53) is connected to the first line (51) via at least one first capacitor (61) and to the second line (52) via at least one second capacitor (62), which first connection (21), second connection (22) and third connection (23) are each connected to a star point (40) via an associated circuit arrangement (31, 32, 33), which fourth connection (24) is likewise connected to the star point (40), and which star point (40) is connected to the node point (53) via a controllable switch (45).

Abstract: A rectifier arrangement for rectifying an AC voltage into a DC voltage has connections, circuit arrangements, an interconnection apparatus and an intermediate circuit. Each circuit arrangement has first and second circuit arrangement connections, between which a changeover arrangement and a coil are connected in series with the changeover arrangement. The changeover arrangements are interconnected to the intermediate circuit. The interconnection apparatus is designed to enable at least a first configuration and a second configuration. In the first configuration, the circuit arrangements form a first group and a second group, with two connections connected to the circuit arrangements in the first group, but not to the circuit arrangements in the second group, and two connections are connected to the circuit arrangements in the second group, but not to the circuit arrangements in the first group. In the second configuration, at least one of the connections is connected to all circuit arrangements.

Abstract: A DC filter device includes: a first filter device connection; a second filter device connection; a third filter device connection; a fourth filter device connection; a coil core; at least one first coil arranged on the coil core, the at least one first coil being connected in between the first filter device connection and the third filter device connection; at least one second coil arranged on the coil core, the at least one second coil being connected in between the second filter device connection and the fourth filter device connection; and a third coil arranged on the coil core, the third coil having a first coil connection and a second coil connection. The first coil connection and the second coil connection are connected to one another via a circuit device, which circuit device has a resistor.

Abstract: A rectifier arrangement (20) for rectifying an AC voltage into a DC voltage has connections, circuit arrangements, an interconnection apparatus (26) and an intermediate circuit (50). The connections include first and second connections (22, 21). The intermediate circuit (50) has a first line (51), a second line (52) and at least one capacitor (61, 62) between the first and second lines (51, 52). The circuit arrangements (31, 32, 33, 34, 35, 36) each have a first circuit arrangement connection (A) and a second circuit arrangement connection (B), between which a changeover arrangement (92) and a coil (91) are connected in series. The interconnection apparatus (26) enables at least: a first configuration in which the first connection (22) is connected to at least one first circuit arrangement connection (A), and a second configuration in which the first connection (22) is connected to at least one second circuit arrangement connection (B).

Abstract: A rectifier assembly (20) for rectifying an AC voltage into a DC voltage has at least one first terminal (21, 22, 23), a second terminal (24) and an intermediate circuit (50). The first terminal (21, 22, 23) is connected via a circuit (31, 32, 33) to a neutral point (40), and the second terminal (24) is connected to the neutral point (40). The circuit arrangement (31, 32, 33) has a first branch (81) and a second branch (82) connected in parallel with the first branch (81). Both branches (81, 82) comprise a changeover arrangement (92, 93) and a coil (91, 94) connected in series with the changeover arrangement. The coil (91) in the first branch (81) is on the side of the changeover arrangement (92) averted from the neutral point (40), and the coil (94) in the second branch (82) is on the side facing the neutral point (40).

Abstract: The present invention relates to PD-1-CD28 fusion proteins, nucleic acid molecules, vectors, transduced cells carrying nucleic acid molecules or vectors of the present invention or expressing the fusion proteins of the present invention, methods and kits comprising the nucleic acid molecules, vectors and/or the fusion proteins of the present invention. The invention also provides the use of said transduced cells in a method for the treatment of particular diseases as well as a pharmaceutical composition/medicament comprising said transduced cells expressing the fusion proteins of the present invention for use in a method of treating of diseases, in particular in the medical intervention of diseases characterized by PD-L1 and/or PD-L2 expression.

Abstract: A method for controlling a charging apparatus of a vehicle, in particular an electric or hybrid vehicle, wherein the charging apparatus has a charging device including a protection and monitoring device. The vehicle includes a high-voltage on-board power system and an electrical energy storage apparatus connected to the high-voltage on-board power system. The method includes electrically connecting the high-voltage on-board power system to charging connections of an energy supply system by the charging apparatus. The charging connections include a neutral conductor, a protective conductor and at least one phase conductor. A protective conductor resistance is detected between the neutral conductor and the protective conductor by feeding in a test current by the protection and monitoring device. A frequency of the test current is filtered out of the compensation frequency range on a narrowband basis.

Abstract: A compensation device (20) for compensating for a discharge current has a compensation current generation device (28), a potential generation device (150), active conductor terminals (61, 62, 63, 64) and a PE conductor terminal (65), which active conductor terminals (61, 62, 63, 64) have a first active conductor terminal (61) and a second active conductor terminal (62; 64), which potential generation device (150) is interconnected with the first active conductor terminal (61) and has a potential generation device terminal (155), which potential generation device (150) is designed to provide a potential at the potential generation device terminal (155) which at least temporarily differs from the potential at the first active conductor terminal (61), and which compensation current generation device (28) is designed to effect a compensation current (I_COMP) between the potential generation device terminal (155) and the PE conductor terminal (65).